Finerenone Improves Cardio-Renal Outcomes 08/06/26
Welcome to Cardiology Today â Recorded August 06, 2026. This episode summarizes 5 key cardiology studies on topics like diabetes and cardiometabolic risk factors. Key takeaway: Finerenone Improves Cardio-Renal Outcomes.
Article Links:
Article 1: Conservative Oxygen for Unresponsive Patients after Cardiac Arrest. (The New England journal of medicine)
Article 2: Finerenone in Persons with Chronic Kidney Disease without Diabetes. (The New England journal of medicine)
Article 3: Treatment of Cardiometabolic Risk Factors Among U.S. Adults With Cardiovascular-Kidney-Metabolic Syndrome. (Journal of the American College of Cardiology)
Article 4: Effects of Finerenone on Sudden Death Across the Cardio-Kidney-Metabolic Landscape: A FINE-HEART Analysis. (Journal of the American College of Cardiology)
Article 5: Periodontitis, epicardial adipose tissue and coronary events: the Swedish Cardiopulmonary Bioimage Study. (European heart journal)
Full episode page: https://podcast.explainheart.com/podcast/finerenone-improves-cardio-renal-outcomes-08-06-26/
đ Featured Articles
Article 1: Conservative Oxygen for Unresponsive Patients after Cardiac Arrest.
Journal: The New England journal of medicine
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/42267831
Summary: This study randomized unresponsive adults receiving mechanical ventilation in the intensive care unit after cardiac arrest to either conservative or liberal oxygen therapy. It compared the clinical impact of distinct arterial oxygen saturation targets following resuscitation. The research specifically evaluated whether limiting oxygen exposure, as opposed to a more liberal approach, affects the likelihood of survival with a favorable functional outcome. This investigation clarifies optimal oxygen management strategies for post-cardiac arrest care.
Article 2: Finerenone in Persons with Chronic Kidney Disease without Diabetes.
Journal: The New England journal of medicine
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/42246672
Summary: Previous randomized trials showed that finerenone, a nonsteroidal mineralocorticoid receptor antagonist, improved kidney and cardiovascular outcomes in patients with type two diabetes and chronic kidney disease. This study randomized adults without diabetes who had chronic kidney disease and albuminuria. Participants had an estimated glomerular filtration rate between 25 and less than 90 milliliters per minute per 1.73 square meters of body-surface area. The research evaluated finerenone’s effects on kidney and cardiovascular outcomes in this specific non-diabetic patient population.
Article 3: Treatment of Cardiometabolic Risk Factors Among U.S. Adults With Cardiovascular-Kidney-Metabolic Syndrome.
Journal: Journal of the American College of Cardiology
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/42307495
Summary: Adults With Cardiovascular-Kidney-Metabolic Syndrome. This study characterized national treatment rates of major cardiometabolic risk factors among U.S. adults with cardiovascular-kidney-metabolic syndrome. It identified contemporary treatment patterns for hypertension and diabetes in this high-risk population. The research clarified intervention targets within the interconnected cardiometabolic, kidney, and cardiovascular disease landscape. This characterization provides a foundation for defining optimal intervention strategies amid rising cardiovascular mortality.
Article 4: Effects of Finerenone on Sudden Death Across the Cardio-Kidney-Metabolic Landscape: A FINE-HEART Analysis.
Journal: Journal of the American College of Cardiology
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/42233928
Summary: Finerenone, a nonsteroidal mineralocorticoid receptor antagonist, demonstrated improved cardiovascular and kidney outcomes in patients with cardiovascular-kidney-metabolic syndrome. The FINE-HEART analysis specifically investigated the effects of finerenone on sudden death within this patient population. This prespecified analysis pooled participant-level data from three placebo-controlled trials of finerenone. It meticulously examined independent predictors of sudden death and finerenone’s impact on this outcome.
Article 5: Periodontitis, epicardial adipose tissue and coronary events: the Swedish Cardiopulmonary Bioimage Study.
Journal: European heart journal
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/42555521
Summary: This study investigated the mechanistic role of subclinical atherosclerosis in the relationship between periodontitis and coronary heart disease. Researchers examined whether subclinical atherosclerosis mediates the association between periodontitis and incident coronary heart disease. The study also evaluated how a specific periodontitis phenotype modifies subclinical coronary atherosclerosis and its association with epicardial adipose tissue attenuation, a marker of inflammation. This research clarifies the complex interplay between oral health and cardiovascular disease mechanisms.
đ Transcript
Today’s date is August 06, 2026. Welcome to Cardiology Today. Here are the latest research findings.
Article number one. Conservative Oxygen for Unresponsive Patients after Cardiac Arrest. This study randomized unresponsive adults receiving mechanical ventilation in the intensive care unit after cardiac arrest to either conservative or liberal oxygen therapy. It compared the clinical impact of distinct arterial oxygen saturation targets following resuscitation. The research specifically evaluated whether limiting oxygen exposure, as opposed to a more liberal approach, affects the likelihood of survival with a favorable functional outcome. This investigation clarifies optimal oxygen management strategies for post-cardiac arrest care.
Article number two. Finerenone in Persons with Chronic Kidney Disease without Diabetes. Previous randomized trials showed that finerenone, a nonsteroidal mineralocorticoid receptor antagonist, improved kidney and cardiovascular outcomes in patients with type two diabetes and chronic kidney disease. This study randomized adults without diabetes who had chronic kidney disease and albuminuria. Participants had an estimated glomerular filtration rate between 25 and less than 90 milliliters per minute per 1.73 square meters of body-surface area. The research evaluated finerenone’s effects on kidney and cardiovascular outcomes in this specific non-diabetic patient population.
Article number three. Treatment of Cardiometabolic Risk Factors Among U.S. Adults With Cardiovascular-Kidney-Metabolic Syndrome. This study characterized national treatment rates of major cardiometabolic risk factors among U.S. adults with cardiovascular-kidney-metabolic syndrome. It identified contemporary treatment patterns for hypertension and diabetes in this high-risk population. The research clarified intervention targets within the interconnected cardiometabolic, kidney, and cardiovascular disease landscape. This characterization provides a foundation for defining optimal intervention strategies amid rising cardiovascular mortality.
Article number four. Effects of Finerenone on Sudden Death Across the Cardio-Kidney-Metabolic Landscape: A FINE-HEART Analysis. Finerenone, a nonsteroidal mineralocorticoid receptor antagonist, demonstrated improved cardiovascular and kidney outcomes in patients with cardiovascular-kidney-metabolic syndrome. The FINE-HEART analysis specifically investigated the effects of finerenone on sudden death within this patient population. This prespecified analysis pooled participant-level data from three placebo-controlled trials of finerenone. It meticulously examined independent predictors of sudden death and finerenone’s impact on this outcome.
Article number five. Periodontitis, epicardial adipose tissue and coronary events: the Swedish Cardiopulmonary Bioimage Study. This study investigated the mechanistic role of subclinical atherosclerosis in the relationship between periodontitis and coronary heart disease. Researchers examined whether subclinical atherosclerosis mediates the association between periodontitis and incident coronary heart disease. The study also evaluated how a specific periodontitis phenotype modifies subclinical coronary atherosclerosis and its association with epicardial adipose tissue attenuation, a marker of inflammation. This research clarifies the complex interplay between oral health and cardiovascular disease mechanisms.
Thank you for listening. Don’t forget to subscribe.
đ Keywords
diabetes, cardiometabolic risk factors, albuminuria, sudden death, intensive care unit, coronary heart disease, cardiovascular-kidney-metabolic syndrome, resuscitation, periodontitis, mineralocorticoid receptor antagonist, cardiac arrest, mechanical ventilation, finerenone, cardiovascular outcomes, oxygen therapy, nonsteroidal mineralocorticoid receptor antagonist, chronic kidney disease, hypertension, subclinical atherosclerosis, inflammation, epicardial adipose tissue, treatment patterns, estimated glomerular filtration rate.
âšī¸ About
Concise summaries of cardiovascular research for professionals.
Subscribe âĸ Share âĸ Follow